L. KENT SMITH, M.D.; RUSSELL V. LUEPKER, M.D.; SARAH S. ROTHCHILD, M.S.; ALBERT GILLIS, M.P.H.; LEON KOCHMAN, M.D.; J. RICHARD WARBASSE, M.D., F.A.C.P.
A lipid intervention clinic screened 4000 employees (89% participation) and identified 150 type IV subjects (top 5 percentile triglyceride values, 100% initial participation, 6% drop out). The 150 healthy type IV subjects, ages 20 to 49, were randomly divided into treatment subgroups: A, treatment by clinic nutritionist and physician with the National Heart and Lung Institute's type IV diet for 6 weeks, then diet plus Clofibrate for 18 weeks; B, same treatment by private physician; C, no intervention for 24 weeks, subjects advised of abnormality. The group A mean fasting serum triglyceride of 407 mg/dl declined 50% at 6 weeks, 61% at 12 weeks, and was unchanged at 24 weeks (P < 0.0005 at 6, 12, 24 weeks). Group B triglyceride decreased 42%, 50%, 41% (P < 0.0005 at 6, 12, 24 weeks). Group C triglyceride declined 20%, 1st to 24th week. Body weight decreased 8% (A) and 4% (B) at 6 weeks (P < 0.0005) and was unchanged at 24 weeks. The maximum cholesterol decrease (A) was 11% (P < 0.0005). Type IV hyperlipoproteinemia can readily be identified in a working population; treatment by clinic or private physician will markedly lower fasting serum triglyceride values in apparently healthy type IV subjects for at least 24 weeks.
SMITH LK, LUEPKER RV, ROTHCHILD SS, GILLIS A, KOCHMAN L, WARBASSE JR. Management of Type IV Hyperlipoproteinemia: Evaluation of Practical Clinical Approaches. Ann Intern Med. ;84:22–28. doi: 10.7326/0003-4819-84-1-22
Download citation file:
Published: Ann Intern Med. 1976;84(1):22-28.
Cardiology, Coronary Risk Factors, Dyslipidemia.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use